<!DOCTYPE html>
<html manifest="manifest.manifest">
<head>
	<meta http-equiv=Content-Type content="text/html; charset=utf-8">
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
  
	<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="manifest" href="/manifest.json">	
	<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<link rel="stylesheet" href="mystyle.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>
	<script>
	    		$(function(){
			$("[data-role='header'], [data-role='footer']").toolbar();
		});
  	  $(document).one('pagebeforecreate', function () {
	        $('input[data-type="search"]').val("");
	    	        $.get("panel.html", function (data2) {
            $.mobile.pageContainer.prepend(data2);
              $("[data-role=panel]").panel().enhanceWithin();
        }, "html");
	           $.get("header.html", function (data) {
      $.mobile.pageContainer.prepend(data);
      $("[data-role='header']").toolbar().enhanceWithin();
    }, "html");
    $.get("footer.html", function (data) {
      $.mobile.pageContainer.append(data);
      $("[data-role='footer']").toolbar().enhanceWithin();
    }, "html");
        $('.WordSection1').wrap('<div role="main" class="ui-content">');
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $.mobile.pageContainer.enhanceWithin();
	  });
	        $(document).bind( "pagechange", function( ) {
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $('.tableCont').enhanceWithin();
      } );
			// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}
	</script>  
</head>

<body lang=EN-GB link=blue vlink=purple>

<div class=WordSection1>

<p class=Heading>Adults with severe COVID-19</p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><b><i><span
style='font-family:"Arial","sans-serif"'>Executive summary</span></i></b></span></p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><b><span
style='font-family:"Arial","sans-serif"'>Introduction</span></b></span><span
class=eop><b>&nbsp;</b></span></p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><span
style='font-size:11.0pt;font-family:"Arial","sans-serif"'>This guideline
assumes that an adult patient has been diagnosed with COVID-19 or that the
clinical picture is highly suspicious for COVID-19. A small group of patients
who contract COVID-19 will become very unwell with it. </span></span></p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><b><span
style='font-family:"Arial","sans-serif"'>Target User</span></b></span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=normaltextrun>Nurses</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=normaltextrun>Doctors</span></p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><b><span
style='font-family:"Arial","sans-serif"'>Target area of use</span></b></span></p>

<p class=MsoListParagraph style='text-indent:-18.0pt'><span style='font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=normaltextrun>Ward</span></p>

<h2>Key areas of focus / New additions / Changes&nbsp;&nbsp;</h2>

<p class=paragraph style='margin-left:36.0pt;text-indent:-18.0pt;vertical-align:
baseline'><span class=normaltextrun><span style='font-size:11.0pt;font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><span class=normaltextrun><span style='font-size:11.0pt;
font-family:"Arial","sans-serif"'>Identification of those who may become
unwell. </span></span></p>

<p class=paragraph style='margin-left:36.0pt;text-indent:-18.0pt;vertical-align:
baseline'><span class=normaltextrun><span style='font-size:11.0pt;font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><span class=normaltextrun><span style='font-size:11.0pt;
font-family:"Arial","sans-serif"'>Management of complications</span></span></p>

<p class=paragraph style='margin-left:36.0pt;text-indent:-18.0pt;vertical-align:
baseline'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=normaltextrun><span style='font-size:11.0pt;
font-family:"Arial","sans-serif"'>The importance of PPE in all circumstances</span></span></p>

<p class=paragraph style='vertical-align:baseline'><span class=normaltextrun><b><span
style='font-family:"Arial","sans-serif"'>Limitations</span></b></span></p>

<p class=paragraph style='margin-left:36.0pt;text-indent:-18.0pt;vertical-align:
baseline'><span class=normaltextrun><span style='font-size:11.0pt;font-family:
Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><span class=normaltextrun><span style='font-size:11.0pt;
font-family:"Arial","sans-serif"'>We lack access to HDU/ITU level care and
cannot ventilate patients. </span></span></p>

<p class=paragraph style='margin-left:36.0pt;text-indent:-18.0pt;vertical-align:
baseline'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span class=normaltextrun><span style='font-size:11.0pt;
font-family:"Arial","sans-serif"'>We have two negative pressure rooms.</span></span></p>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br clear=all
style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
style='font-size:12.0pt'>&nbsp;</span></b></p>

<h2>Presenting symptoms and signs</h2>

<p class=MsoNormal>There are two groups of patients to think about as high risk
in the COVID-19 outbreak:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span><b>Those who
have become very unwell with COVID-19 as their only problem.</b> This group
seems to present to hospital 5-12 days after the start of symptoms. They can
develop Acute Respiratory Distress Syndrome (ARDS) and become very unwell. They
comprise patients who have diabetes, chronic respiratory conditions (including
severe asthma and COPD), chronic heart conditions (including uncontrolled
hypertension) and immunosuppression (which in our setting is HIV/AIDS, steroids
and methotrexate use). Also, lymphopenia, especially when progressively
worsening seems to be a marker of likely poorer prognosis.</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span><b>Those
patients who have another medical condition that has been complicated by
contracting COVID-19</b>. </p>

<h3>Clinical presentation of COVID-19 Pneumonia (severe &amp; critical
COVID-19)</h3>

<p class=MsoNormal>Clinically apparent COVID-19 primarily presents as a
febrile, flu-like illness with recovery in approximately 80 % of cases. </p>

<p class=MsoNormal>In around 20% of cases this flu-like illness progresses to a
pneumonia over a period of 5-12 days from symptom onset and in a small number
of cases (approximately 5% of total clinically apparent cases) this progresses
further to ARDS, multi-organ failure, circulatory collapse &amp; death. COVID
with hypoxia, tachypnoea, or widespread CXR changes (&gt; 50% lungs on CXR) is
considered severe disease, whilst the presence of ARDS, multi-organ failure or
circulatory collapse would constitute critical disease. </p>

<p class=MsoNormal>Fever can be prolonged, lasting up to 14 days even in
relatively uncomplicated cases, though persistence of fever after 7 days
suggests that a more severe course may be developing. </p>

<p class=MsoNormal>As disease become more common, more atypical presentations
may present including acute abdominal pain, diarrhoea, delirium etc. </p>

<h3>Differentiating COVID-19 from bacterial pneumonia (CAP)</h3>

<p class=MsoNormal>The following are suggestive of COVID-19 rather than CAP:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Travel from outside the Gambia</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>A history of close contact with confirmed / suspected case(s) of
COVID-19</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Household contacts with acute cough, fever, breathlessness</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>High rapidly spiking fever (peaks &gt; 37.8<sup>0</sup>C)</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Several days history before respiratory deterioration</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>History of loss of sense of smell / taste is highly suggestive
and should be sought in all patients</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>History of myalgia and /or headache</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Bilateral respiratory signs</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Bilateral infiltrates on the chest X ray, with a non-lobar, lower
zone and peripheral predominance</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Normal WCC with relative lymphopenia and absence of neutrophilia.</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Significant pleural effusion is uncommon in COVID-19</p>

<p class=MsoListParagraphCxSpLast style='margin-left:14.2pt'>&nbsp;</p>

<u><span style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:14.2pt'><u>Other
laboratory features commonly seen:</u></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Slightly elevated liver enzymes (ALT/AST)</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Low platelets</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Raised LDH</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Raised troponin</p>

<p class=MsoNormal>Currently COVID-19 can only be confirmed by a viral PCR,
usually of a throat or nasopharyngeal swab sample. Estimates of the sensitivity
of the vary from 80-90%, probably worse later in disease when the virus is
predominantly in the lungs. Specificity is good. Therefore remember two things:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Imaging changes (CXR or US in our context) with symptoms and lab
tests suggestive of COVID-19 with a negative test can still be COVID-19. This
is particularly true at the time when pneumonia becomes a predominant feature,
and also becomes more of a problem as the disease spreads (pre-test probability
rises and the test performs worse). </p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If someone has COVID-19, they can still have another infection or
health problem complicating their presentation. </p>

<h2>Management </h2>

<p class=MsoNormal>All patients must be assessed for severity and a decision
made about plans for treatment escalation at the time of admission. This is
covered in another guideline.</p>

<p class=Body>Currently, the management of COVD-19 is <b>supportive</b>. </p>

<p class=Body>There have been several treatments suggested that may be of
benefit. At this moment, <b>only patients enrolled in a clinical trial</b>
should receive therapy directed at COVID-19. This group of medicines include
high dose corticosteroids (in the absence of bronchoconstriction),
hydroxychloroquine, azithromycin and anti-retroviral medications such as Lopinavir/ritonavir.</p>

<p class=Body><b>In all circumstances</b>, appropriate PPE must be worn. If a
patient becomes critically unwell, then staff should still take the time to don
the PPE in a safe and proper manner.</p>

<p class=Body>Decisions on whether patients with COVID-19 need admission are
likely to vary depending on the state of the epidemic at the time and the
public health strategy. Where containment is the objective public health
authorities may request the admission of all patients. If resources and beds
become scarce, this may change to those meeting specific criteria (eg at risk
of deterioration, needing oxygen or palliation). </p>

<p class=MsoNormal><b><u>Respiratory support</u></b>: <span lang=EN-US>Give
oxygen to patients with SARI and resp distress, hypoxaemia, seizures or shock
and target SpO2 &gt; or equal to 94%. Once stable, target saturation is &gt;
90% in non-pregnant and 92 – 95% in pregnant patients. (</span>This is not a
guide on how many litres of oxygen to give them but a target for the optimum
saturations once the oxygen is started. Oxygen should be turned down if
saturations are consistently 99-100%).</p>

<p class=Body>It may help in all patients, to lie them in a prone position i.e.
on their front. </p>

<p class=Body>BiPAP or CPAP are indicated when patients are classed as
critically ill. If BiPAP or CPAP are available, they are likely to be the
ceiling of care for many patients in The Gambia. CPAP and BiPAP are aerosol
generating so should ideally be deployed in a neutral or negative pressure
room. It may become necessary to cohort (place together) patients with proven
or suspected COVID-19 and COVID-19 patients on CPAP or BiPAP.</p>

<p class=Body>Intubation and ventilation may be available in a few cases
offsite, but the feasibility of this is currently unknown. With mortality in
well-resourced settings of 66% for selected patients put on a ventilator with
COVID-19, it will be necessary to select specific patients that may benefit
from this resource intensive procedure. Intubation should be done by the most
skilled operative using strict PPE. </p>

<p class=Body><b><u>Fever</u></b>: Give due consideration as to why the fever
is being treated. Generally, bringing down a patient's fever will likely make
them feel better but not necessarily change how long they are unwell for. The
exception to this is in patients with haemodynamic instability where reducing
fever may reduce the risk of hypoxic tissue damage. </p>

<p class=Body>There is currently no evidence that NSAIDs are associated with
extra morbidity and mortality in COVID-19. There is some evidence from other
respiratory infections that NSAIDS will increase stroke and heart disease risk
in susceptible patients. We recommend the use paracetamol first and then
ibuprofen at as little a quantity as possible, for as short a time as possible.</p>

<p class=Body><b><u>Pain</u></b>: Please, see above under fever above. If
unresponsive to paracetamol, then use the WHO pain ladder. </p>

<p class=Body><b><u>Underlying medical conditions</u></b>: Individual decisions
should be made about each patient as they come, to manage their underlying
condition alongside their acute COVID-19 as needed. There are a few areas of
controversy to address:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>ACEi/ARB:</b> There is no current evidence to support that
patients will either gain protection or come to harm from these medications.
Continuing the medication where it is needed while the patient is unwell is
reasonable. However, given that these patients are likely to be acutely unwell,
they are likely to be at risk of hypotension and renal injury. In such a
situation, consideration should be given to stopping them during the infection
and re-starting these medications after recovery. </p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Asthma/COPD/Post TB lung</b>: These patients may benefit from
steroids. Endeavour to use the lowest effective dose and where possible reduce
the dose to less than 20mg for adults. However, given our limited therapy for
bronchoconstriction, higher doses of steroids may still be needed.</p>

<p class=Body><b><u>Secondary bacterial infection</u></b>: Patients who worsen
unexpectedly, whose cough becomes productive, who have neutrophil leucocytosis
or who have new lateralising signs and symptoms should be considered for
treatment with antibiotics aimed at bacterial pneumonia. It may be necessary
for some patients (eg. critical cases with unclear aetiology) to start
antibiotics when they are unwell and then stop them if the test for COVID-19
comes back and explains their presentation. </p>

<p class=Body><b><u>Pressure area care</u></b>: Ensure that patients who become
bed bound are turned regularly (2-3 hourly) by nursing staff to stop pressure
area damage.</p>

<p class=Body><b><u>Fluid and nutrition</u></b>: Patients should be encouraged
to eat but anorexia and anosmia are a common feature. Food intake is not vital
and people will recover an appetite and their lost weight after recovery. </p>

<p class=Body>Fluid should be encouraged orally and then given NG first and
ultimately intravenously if that does not work. If iv fluids are given, the aim
is to maintain euvolaemia, taking into account insensible losses. Boluses
should only be used if a patient is obviously shocked. </p>

<p class=Body><b><u>Monitoring</u></b>: Hospitalised patients should be
monitored regularly to identify deterioration. Saturations are particularly
important. Early warning scores or specific severity scores should be used according
to current practice.</p>

<h2>Key Issues for Nursing care</h2>

<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Regular monitoring of a potential unstable group of patients</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Adhering to PPE to ensure staff and wider public safety</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Communication with patients and families</p>

<h2>References</h2>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Aronson J, Ferner R. Angiotensin converting
enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - CEBM
[Internet]. CEBM. 2020 [cited 24 March 2020]. Available from: </span><span
lang=EN-US><a
href="https://www.cebm.net/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.cebm.net/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-blockers-in-covid-19/</span></span></a></span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>De Simone G. Position Statement of the ESC
Council on Hypertension on ACE-Inhibitors and Angi [Internet]. Escardio.org.
2020 [cited 24 March 2020]. Available from: </span><span lang=EN-US><a
href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang</span></span></a></span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Ramsay M. Contraindications and special
considerations [Internet]. Assets.publishing.service.gov.uk. 2020 [cited 25
March 2020]. Available from: </span><span lang=EN-US><a
href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf</span></span></a></span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Heneghan C, Brassey J. NSAIDs in Acute
Respiratory Infection - CEBM [Internet]. CEBM. 2020 [cited 25 March 2020].
Available from: </span><span lang=EN-US><a
href="https://www.cebm.net/oxford-covid-19/nsaids-in-acute-respiratory-infection/"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.cebm.net/oxford-covid-19/nsaids-in-acute-respiratory-infection/</span></span></a></span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'> </span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Clinical management of persons admitted to
hospital with suspected COVID-19 infection [Internet]. England.nhs.uk. 2020
[cited 25 March 2020]. Available from: </span><span lang=EN-US><a
href="https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020.pdf"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/clinical-management-of-persons-admitted-to-hospita-v1-19-march-2020.pdf</span></span></a></span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'> </span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Myth busters [Internet]. Who.int. 2020
[cited 25 March 2020]. Available from: </span><span lang=EN-US><a
href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters</span></span></a></span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'> </span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Kalil A. Treating COVID-19—Off-Label Drug
Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA
[Internet]. 2020 [cited 25 March 2020];. Available from: </span><span
lang=EN-US><a
href="https://jamanetwork.com/journals/jama/fullarticle/2763802?utm_source=twitter&amp;utm_campaign=content-shareicons&amp;utm_content=article_engagement&amp;utm_medium=social&amp;utm_term=032420#.XnprLOb6jWY.twitter"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://jamanetwork.com/journals/jama/fullarticle/2763802?utm_source=twitter&amp;utm_campaign=content-shareicons&amp;utm_content=article_engagement&amp;utm_medium=social&amp;utm_term=032420#.XnprLOb6jWY.twitter</span></span></a></span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'> </span></p>

<p class=Default><span style='font-size:10.0pt;font-family:"Arial","sans-serif";
color:windowtext;background:white'>Self-isolation advice - Coronavirus
(COVID-19) [Internet]. nhs.uk. 2020 [cited 25 March 2020]. Available from</span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'>: </span><span lang=EN-US><a
href="https://www.nhs.uk/conditions/coronavirus-covid-19/self-isolation-advice/"><span
class=Hyperlink0><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";
background:white'>https://www.nhs.uk/conditions/coronavirus-covid-19/self-isolation-advice/</span></span></a></span><span
style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#666666;
background:white'> </span></p>

<p class=MsoNormal><span style='font-size:10.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Written
  by:</b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Name: Will
  Taylor</p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Date: 30
  March 2020</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Reviewed
  by:</b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Name: Babatunde
  Awokola</p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Date: 07
  April 2020</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Reviewed
  by:</b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Name: <span
  class=normaltextrun>Behzad Nadjm</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Date: 10
  April 2020 </p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Version:</b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Change
  history:</b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>Review
  due date:</b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>1.0</p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>New
  document</p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>10 April
  2022</p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>Review
  Comments (<i>if applicable)</i></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'>&nbsp;</p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
